Home › Type 1 Diabetes › NCT07293715

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

Who can join

Ages 18 and older · Women

Inclusion Criteria

* Pregnant individuals
* ≥ 18 years old
* Type 1 diabetes
* Intention for vaginal delivery and admitted to Labor and Delivery
* Singleton, non-anomalous fetus
* Gestational age greater than or equal to 35 weeks gestation.
* Cervical dilation is less than 6 cm.
* Delivering at the study institution

Exclusion criteria:

* Scheduled cesarean delivery
* Cervical dilation ≥ 6 cm on presentation to L\&D
* Receipt of antenatal corticosteroids within 7 days of randomization
* Fetal demise
* Major fetal anomaly (attached)
* Multiple gestation
* Non-English speaking

About the study

PRISM-TID is a single center non-inferiority randomized controlled trial of permissive intrapartum glucose management (intervention) versus strict intrapartum glucose management (standard of care) among pregnant individuals with type 1 diabetes (T1D) using hybrid closed loop therapy (HCL) who are admitted for labor management. Participants will be randomized in a 1:1 fashion to one of two intrapartum glycemic control options: permissive (70-140 mg/dL) or strict (70-110 mg/dL). The primary aim of this trial it to demonstrate that permissive intrapartum glucose management is not associated with an increased risk of neonatal dysglycemia compared with strict intrapartum glucose management.

What is being tested

• Insulin (drug)
• DEXCOM Continuous Glucose Monitor (device)

Sponsor: Ohio State University · Participants: 44 · Started: Feb 25, 2026

Contact the study team

• Anna Brewton, MD · Phone: 614-293-8045

Official record on ClinicalTrials.gov — NCT07293715

Locations in the U.S.

Conditions

• Type 1 Diabetes

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.